Sonire Therapeutics started its U.S.-based Sunrise II study of Suizenji, an ultrasound-guided high-intensity focused ultrasound (HIFU) system intended to ablate pancreatic tumors. The trial initiation comes after Sonire closed an $18 million Series A financing round on April 15. The company’s approach is focused on a device-led modality, moving from development into U.S. clinical evaluation for pancreatic cancer, a setting where diagnosis and treatment timing are tightly constrained. For biopharma and med-tech investors, the Sunrise II launch adds a new clinical runway for ultrasound-based tumor ablation and could inform payer and clinical adoption depending on safety and early efficacy outcomes.